New Delhi: There is currently a shortage of COVID-19 vaccines in the country, but the problem won’t persist long as five more vaccines are likely to be approved by Q3 of this year, according to ANI.
Sputnik V, the Russian vaccine being made in India by Dr Reddy’s and a few other companies, could be approved for emergency use in the next 10 days.
Other vaccines in the pipeline are Johnson & Johnson being made by Biological E, Novavax made in collaboration with Serum Institute of India, Zydus Cadila’s vaccine and Bharat Biotech’s Intranasal Vaccine.
For Sputnik V, Russian Direct Investment Fund (RDIF) is financing Indian pharma companies Dr Reddy’s Laboratories, Hetero Biopharma, Gland Pharma, Stelis Biopharma and Vichrow Biotech. As many as 850 million doses will be made in India.
Johnson & Johnson and Zydus Cadilla vaccines are expected to be available by August. Novovax is expected to be launched by September and Bharat Biotech’s nasal vaccine is expected to come by October.
